Literature DB >> 1722192

FK-506 prevents diabetes in diabetes-prone BB/Wor rats.

F Nicoletti1, P L Meroni, W Barcellini, S Grasso, M O Borghi, M Lunetta, R Di Marco, S Stefani, L Mughini.   

Abstract

The effect of the immunosuppressant FK-506 on the development of diabetes in BB/Wor rats was investigated. Using a treatment schedule (25 micrograms i.m. from day 27 to 120), not associated with detectable general ill effects, this drug was found to completely inhibit the appearance hyperglycemia and to reduce the histological signs of pancreatic insulitis. The treatment was also able to reduce the percentages of Ia+ T-lymphocytes and to block the appearance of detectable serum levels of gamma interferon (IFN).

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1722192     DOI： 10.1016/0192-0561(91)90057-e

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN： 0192-0561


  3 in total

Review 1.  FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

Authors:  A W Thomson; P B Carroll; J McCauley; J Woo; K Abu-Elmagd; T E Starzl; D H Van Thiel
Journal:  Springer Semin Immunopathol       Date:  1993

2.  Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma.

Authors:  F Nicoletti; R Di Marco; S Morrone; P Zaccone; D Lembo; S Grasso; A Santoni; P L Meroni; K Bendtzen
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

3.  Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin.

Authors:  F Nicoletti; M O Borghi; P L Meroni; W Barcellini; C Fain; R Di Marco; R Menta; H U Schorlemmer; G Bruno; G Magro
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.